Regulatory30 May 2026, 09:41 pm
Astonea Labs: Deviation in IPO Fund Use Approved
AI Summary
Astonea Labs Ltd reported a deviation in the utilization of IPO proceeds for the half year ended March 31, 2026. The deviation, involving reallocation of ₹6.25 Cr towards acquisition of equity shares in Damaira Pharmaceuticals, was approved by the Board on February 27, 2026, and shareholders on March 27, 2026. Out of the initial allocation of ₹37.665 Cr, ₹29.578 Cr has been utilized, with ₹8.087 Cr remaining unutilized as of February 26, 2026. The company has made continuous disclosures to BSE regarding these approvals.
Key Highlights
- Astonea Labs reallocated ₹6.25 Cr from IPO proceeds to acquire Damaira Pharmaceuticals equity.
- Shareholders approved the deviation in IPO fund utilization on March 27, 2026.
- As of Feb 26, 2026, ₹29.578 Cr of the ₹37.665 Cr IPO proceeds have been utilized.
- ₹8.087 Cr remains unutilized from the IPO proceeds as of February 26, 2026.
- The reallocation aims to leverage growth opportunities and strengthen business synergies.
Price Impact
More from ASTONEALAB